We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Successful Treatment of Delayed Localized Necrotizing Inflammatory Myositis After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine: A Case Report.
- Authors
Li, Jennifer Chen; Siglin, Jonathan; Marshall, Michael S; Stemmer-Rachamimov, Anat; Bloom, Seth M; Blumenthal, Kimberly G
- Abstract
Reported adverse reactions to the mRNA-1273 vaccine (Spikevax, Moderna Inc) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) range from mild, local delayed cutaneous reactions to rarer, more serious reactions such as myocarditis. Here, we describe the presentation and successful treatment of delayed, localized necrotizing inflammatory myositis following a third dose of the mRNA-1273 SARS-CoV-2 vaccine. To our knowledge, this is the first report of biopsy-confirmed, delayed inflammatory myositis after administration of an mRNA-1273 SARS-CoV-2 vaccine booster.
- Subjects
SARS-CoV-2; MYOSITIS; TREATMENT delay (Medicine); COVID-19 vaccines; VACCINATION complications; TREATMENT effectiveness
- Publication
Open Forum Infectious Diseases, 2022, Vol 9, Issue 10, p1
- ISSN
2328-8957
- Publication type
Case Study
- DOI
10.1093/ofid/ofac499